Banner - NPPA Connect

Opinion|Videos|April 11, 2025

Determining Follow-Up Approach in Melanoma Based on GEP Risk Level

Author(s)David Cotter, MD, PhD

An expert discusses whether the 31-gene expression profile (GEP) risk classification would change treatment guidelines and how the patient’s GEP risk level would influence the approach to surveillance and follow-up.

Episodes in this series

EP. 1 Limitations and Challenges in Skin Cancer Staging Systems

EP. 1 Limitations and Challenges in Skin Cancer Staging Systems

EP. 2 Utility of Molecular Testing in Skin Cancer Risk Assessment

EP. 2 Utility of Molecular Testing in Skin Cancer Risk Assessment

EP. 3 Gene Expression Profiling and Other Molecular Tests Utilized for Melanoma and Squamous Cell Carcinoma

EP. 3 Gene Expression Profiling and Other Molecular Tests Utilized for Melanoma and Squamous Cell Carcinoma

EP. 4 Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma

EP. 4 Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma

EP. 5 De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC

EP. 5 De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC

EP. 6 Key Takeaways on GEP Testing in Melanoma and SCC

EP. 6 Key Takeaways on GEP Testing in Melanoma and SCC

EP. 7 Determining Follow-Up Approach in Melanoma Based on GEP Risk Level

EP. 7 Determining Follow-Up Approach in Melanoma Based on GEP Risk Level

EP. 8 Transforming Risk Stratification in Melanoma and Squamous Cell Carcinoma

EP. 8 Transforming Risk Stratification in Melanoma and Squamous Cell Carcinoma

Video content above is prompted by the following:

Does the 31-GEP risk classification change your treatment guidelines?
How would you approach surveillance and follow-up with this patient after knowing their GEP risk level?

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

1 expert is featured in this series

Addressing Steroid Fear with Non-Steroidal Treatment Options in Psoriasis

ByTina Bhutani-Jacques, MD

September 4th 2026

1 expert is featured in this series

Setting Realistic Treatment Goals for Localized Plaque Psoriasis

ByTina Bhutani-Jacques, MD

September 4th 2026

1 expert is featured in this series

Skin Clearance and PsA Prevention with Biologics in Psoriasis

ByBruce Strober, MD, PhD

September 1st 2026

1 expert is featured in this series

Case 3: Redefining How We Classify Psoriasis Severity

ByTina Bhutani-Jacques, MD

August 28th 2026

1 expert is featured in this series

Why One Foam Works for Scalp and Body Psoriasis

ByTina Bhutani-Jacques, MD

August 28th 2026

Latest CME

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Trending on Dermatology Times

AbbVie Completes $10.9 Billion Apogee Acquisition, Adds Zumilokibart to AD Pipeline

Uncovering the Autoimmune Links & Systemic Impact of Chronic Spontaneous Urticaria

10 Skin Cancer Exam Tips

Dermatology Times Conferences & Meetings Calendar: September 2026

Early Recognition and Psychosocial Impact in Male Pattern Hair Loss